International, Randomized, Open Label Study to Compare the Safety and Efficacy of Lixisenatide vs. Sulfonylurea on Top of Basal Insulin Treatment in Type 2 Diabetes Mellitus Subjects Who Elect to Fast During Ramadan
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Lixisenatide (Primary) ; Insulin; Metformin; Sulfonylureas
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms LixiRam
- Sponsors Sanofi
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 20 Sep 2017 Status changed from active, no longer recruiting to completed.
- 21 Jun 2017 Planned End Date changed from 30 Sep 2017 to 24 Jul 2017.